TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A case report describes a 50-year-old woman with bipolar disorder whose lithium level rose after she started tirzepatide, followed by tremor, slurred speech and blurred vision. Her symptoms subsided after her lithium dose was reduced, but one case cannot establish that tirzepatide caused the change. A psychiatrist not involved in the report recommends early checks of lithium levels and kidney function when patients start an incretin medicine.
A case report published in the Journal of Clinical Psychopharmacology describes a 50-year-old woman with bipolar disorder whose lithium blood level rose after she began tirzepatide, followed by hand tremor, slurred speech and blurred vision. Her symptoms subsided after her lithium dose was lowered, but the report does not establish that tirzepatide caused the change; clinicians say the case supports monitoring rather than automatically avoiding the medicines together.
The woman had been taking 900 mg of lithium nightly after her dose was gradually increased. Before tirzepatide, a lithium level was 0.7 mmol/L, and testing showed normal kidney function and no electrolyte abnormalities. She later started weekly tirzepatide at 2.5 mg for chronic weight management.
Three weeks after starting tirzepatide, she reported new symptoms that had lasted two days. A trough lithium test the following day measured 1.2 mmol/L. According to the case report, she had not changed her lithium dose or how she took it and had started no other medicines. She did report eating smaller meals, feeling full sooner and experiencing some bloating after beginning tirzepatide.
Her clinicians advised her to reduce lithium to 450 mg nightly, after which the symptoms subsided. A level measured 17 days later was 0.4 mmol/L. She had lost five pounds during three weeks on tirzepatide, but chose with her doctor not to restart it. She was gradually titrated back to 900 mg of lithium nightly.
Monitoring When Starting Tirzepatide
The report matters because lithium requires careful monitoring, and a change in its blood concentration can be clinically important. Tremor, slurred speech and blurred vision were the symptoms reported in this patient; readers should not use a single case to diagnose toxicity or change treatment themselves.
Psychiatrist Jorge Almeida, who was not involved in the report, said patients taking lithium may still be candidates for incretin medicines, which can be used to treat obesity and type 2 diabetes. He described the practical message as early monitoring, not avoidance, and advised checking lithium levels and kidney function within the first few weeks after starting an incretin medicine and again after dose changes. Patients who develop concerning symptoms should contact their prescriber rather than stop either medication on their own.
Products Worth Considering
OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
OMRON VIVA 360+ Body Composition Monitor and Smart Scale
Withings Body Smart Wi-Fi and Bluetooth Smart Scale
As an affiliate, we earn on qualifying purchases.
A Fourth Reported Tirzepatide Case
The case authors, led by Jay Davis of the University of Colorado Anschutz Medical Campus, described this as the fourth reported case of tirzepatide-associated lithium toxicity. That count refers to reported cases, not a measured rate of risk. The authors and outside clinician characterized the evidence as a small but growing set of reports; it does not show how often the interaction occurs or identify which patients may be most vulnerable.
Davis told MedPage Today that a proposed explanation is increased lithium reabsorption associated with reduced oral intake. In this patient’s account, tirzepatide was followed by smaller meals and earlier satiety. That mechanism remains a hypothesis, not a finding proven by the case. The authors note that lithium remains a cornerstone treatment for bipolar disorder, while incretin medicines may benefit people with bipolar disorder who also have obesity or type 2 diabetes.
“The favored mechanism for this medication interaction – increased fractional reabsorption due to decreased oral intake – raises interesting questions about whether and how these medications might be prescribed safely together.”
— Jay Davis, MD, University of Colorado Anschutz Medical Campus
Cause and Risk Remain Unsettled
One case cannot prove causation, and it cannot establish how likely a lithium level increase is for other people taking tirzepatide or similar medicines. The patient’s level rose after treatment began and symptoms improved after the lithium dose was lowered, but that sequence alone does not confirm a drug interaction. The proposed link to reduced food intake also has not been established.
The report does not determine whether the same effect occurs with other incretin medicines, how long any risk may last, or which factors affect it. Although the patient had normal kidney function before tirzepatide, the case does not settle the role of kidney function or other individual differences. More evidence is needed to define the interaction and guide monitoring.
Prescriber Checks and Further Evidence
Almeida recommends that clinicians consider checking lithium levels and kidney function within the first few weeks after a patient on lithium starts an incretin medicine, and repeating checks after dose changes. The case authors call for further caution and a better understanding of possible interactions. The report itself does not set a formal monitoring schedule or change prescribing guidance.
People taking lithium who are considering tirzepatide or another incretin medicine should discuss the combination with their prescriber before starting or changing treatment. Anyone who develops new symptoms should seek advice promptly, rather than adjusting or stopping medication without medical guidance. Whether additional cases or research will clarify the mechanism and frequency of the potential interaction remains unknown.
Key Questions
What happened in the case report?
A woman taking lithium developed tremor, slurred speech and blurred vision three weeks after starting tirzepatide. Her lithium level had risen from 0.7 to 1.2 mmol/L. Her symptoms subsided after her lithium dose was reduced.
Does this prove tirzepatide interacts with lithium?
No. The timing and symptom improvement raise concern, but a single case cannot prove cause and effect or establish how often the issue occurs.
Should people taking lithium avoid tirzepatide?
The outside psychiatrist quoted in the report said the practical message is monitoring, not automatic avoidance. Patients should discuss their own treatment with their prescriber and should not stop either medicine on their own.
What monitoring did the psychiatrist recommend?
Jorge Almeida recommended checking lithium levels and kidney function within the first few weeks after starting an incretin medicine, and again after dose changes. This is his advice in the article, not a formal schedule established by the case report.
What symptoms were reported?
The patient developed tremor in both hands, slurred speech and blurred vision. Anyone taking lithium who experiences new or concerning symptoms should contact their prescriber for guidance.
Source: medpagetoday.com
